Genzyme Beats Expectations, Jumps 12%

Rises on increased revenue and takes other biotechs with it... Genzyme (GENZ) beat all expectations today and investors sent the stock soaring 12.4% to $50.00 per share. The stock was one of the biggest gainers in an overall down market, and it appeared that the good news lifted all boats. With it went Amgen (AMGN), Compugen (CGEN), Celera (CRA), Genentech (DNA), Incyte (INCY), Vical (VICL), MGI Pharma (MOGN), and Icos Corporation (ICOS), all Centient Biotech 200â„¢ companies.

Back to news